Biome FY24 Financial Update
Biome Australia Limited (ASX: BIO) has provided an update on the financial year 2024. Notable Highlights: The company achieved an… Read more
Biome’s Clinically Proven Cholesterol Reducing Probiotic Launched
Biome’s Clinically Proven Cholesterol Reducing Probiotic Launched: ● Biome has launched its new cholesterol lowering probiotic, Biome Cholesterol Probiotic, in… Read more
Biome shares revenue target as part of Vision 27 Strategic Plan
Biome Australia Limited (ASX:BIO) has released a cumulative revenue target for the next three years from FY2025 and FY2027 of… Read more
Biome Australia Quarterly Activities & Appendix 4C June 2024
Biome has released their Quarterly for June 24. It is once again an outstanding report and continues to underline why… Read more
Biome Achieves Record Quarter, Half and Full-Year Sales Revenue (unaudited)
● Biome records ○ ~$13m FY24 sales revenue, up 80% vs PCP ○ ~$7m H2 FY24 sales revenue, up 82%… Read more
Biome expects to exceed FY24 forecast and report second consecutive positive cashflow and EBITDA quarter
Trading Update ● Biome expects to exceed its upgraded revenue forecast of $12.5m for FY24 ● Biome expects to report… Read more
Biome International Market Update and Health Canada approvals
● Following January 2024 launch into health retail in the UK and Ireland, Biome expects FY24 International sales revenue to… Read more
Biome Australia – Company presentation April 2024
Biome Business Opportunity Novel range of Live Biotherapeutics with co-prescribing medication opportunity Landmark IP Deal executed on novel probiotic strains… Read more
Biome Australia – Quarterly Activities & Appendix 4C March 2024
● Biome records first positive quarterly EBITDA (unaudited) in Q3 FY24 ● Biome records first positive quarter of underlying operating… Read more
